Last reviewed · How we verify
Gottfried Wilhelm Leibniz Universität Hannover — Portfolio Competitive Intelligence Brief
2 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| GArTG | GArTG | marketed | ||||
| rTG | rTG | marketed | Enzyme (tissue transglutaminase) | Tissue transglutaminase (TG2/TGM2) | Wound Care / Hemostasis / Surgery |
Therapeutic area mix
- Wound Care / Hemostasis / Surgery · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
Subscribe to ongoing alerts
Every new pipeline event for Gottfried Wilhelm Leibniz Universität Hannover:
- Gottfried Wilhelm Leibniz Universität Hannover pipeline updates — RSS
- Gottfried Wilhelm Leibniz Universität Hannover pipeline updates — Atom
- Gottfried Wilhelm Leibniz Universität Hannover pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Gottfried Wilhelm Leibniz Universität Hannover — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/gottfried-wilhelm-leibniz-universit-t-hannover. Accessed 2026-05-17.